What is Zivâaflibercept made from?

The active ingredient is zivâaflibercept, a recombinant fusion protein that binds VEGFâA, VEGFâB, and placental growth factor (PlGF). It is formulated as a sterile solution for intravenous infusion.

What is Zivâaflibercept trade name?

The most recognized trade name for zivâaflibercept is Zaltrap®.

What is generic name of Zivâaflibercept?

The generic (nonâproprietary) name is zivâaflibercept.

Ziv-aflibercept bulk supplier for pharma manufacturers

Ziv-Aflibercept 25mg/ml Suppliers & Bulk Manufacturers

Q: What is Zivâaflibercept used for?

Zivâaflibercept is used to treat certain types of cancers by inhibiting vascular endothelial growth factor (VEGF), which helps prevent the growth of new blood vessels that tumors need to grow. It is used in combination with chemotherapy for metastatic colorectal cancer and may be studied in other solid tumors.

Q: What company makes Zivâaflibercept?

Zivâaflibercept is manufactured by Sanofi (Zaltrap®) and may also be produced by licensed generic or biosimilar manufacturers in regions where approved.

Q: Where is Zivâaflibercept manufactured?

Zivâaflibercept is manufactured in GMPâcertified biopharmaceutical facilities globally, ensuring quality and safety for intravenous cancer therapy.

Available Forms: Intravenous (IV)

Available Strengths: 25mg/ml

Reference Brands: Zaltrap® (US & EU)

Category: Oncology Cancer Care

Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis. It targets vascular endothelial growth factor (VEGF), preventing tumor blood vessel growth. Available as an intravenous (IV) injection with a strength of 25 mg/mL, it is used in combination with chemotherapy for mCRC treatment. Ziv-aflibercept is available in both the US and EU, helping improve outcomes for patients with advanced colorectal cancer.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis – the process of new blood vessel formation that tumors need to grow. It works by targeting and binding to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with receptors on endothelial cells, thus blocking tumor blood vessel formation. Ziv-aflibercept is typically administered in combination with chemotherapy and is available in the US and EU in an intravenous (IV) formulation

Ziv-Aflibercept — third party manufacturing & bulk supply

Ziv-Aflibercept 25mg/ml is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ziv-Aflibercept is supplied as Intravenous (IV) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ziv-Aflibercept listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ziv-Aflibercept →

Back to Listing

Frequently Asked Questions

Ziv‑aflibercept is used to treat certain types of cancers by inhibiting vascular endothelial growth factor (VEGF), which helps prevent the growth of new blood vessels that tumors need to grow. It is used in combination with chemotherapy for metastatic colorectal cancer and may be studied in other solid tumors.

The active ingredient is ziv‑aflibercept, a recombinant fusion protein that binds VEGF‑A, VEGF‑B, and placental growth factor (PlGF). It is formulated as a sterile solution for intravenous infusion.

The most recognized trade name for ziv‑aflibercept is Zaltrap®.

Ziv‑aflibercept is manufactured by Sanofi (Zaltrap®) and may also be produced by licensed generic or biosimilar manufacturers in regions where approved.

The generic (non‑proprietary) name is ziv‑aflibercept.

The brand name is Zaltrap®.

Ziv‑aflibercept is manufactured in GMP‑certified biopharmaceutical facilities globally, ensuring quality and safety for intravenous cancer therapy.